Finance

Lists
AGMB:NASDAQ
Agomab Therapeutics NV
US$6.36
0.00%
(0.00) 1D
ኖቬም 13, 4:00:01 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AGMB...
Open
US$6.32
High
US$6.60
Low
US$5.73
Mkt. cap
313.22 ሚ
Avg. vol.
231.32 ሺ
Volume
192.64 ሺ
52-wk high
US$17.82
52-wk low
US$5.73
No. of employees
62
Open
US$6.32
High
US$6.60
Low
US$5.73
Mkt. cap
313.22 ሚ
Avg. vol.
231.32 ሺ
Volume
192.64 ሺ
52-wk high
US$17.82
52-wk low
US$5.73
No. of employees
62
News stories
From web sources and news partners
marketscreener.com
marketscreener.com
·
ከ7 ሰዓቶች በፊት
S&P 500 Posts Weekly Gain as Energy Sector Leads Broad Climb
Traders Union
Traders Union
·
ከ8 ሰዓቶች በፊት
S&P 500 gains $1.2 trillion in a week, Peter Tuchman notes
About Agomab Therapeutics NV
CEO-
Employees62
Founded2017
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteagomab.com
Analyst ratings
Based on 6 analysts giving stock ratings to AGMB in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AGMB in the last 3 months.
Highest
Current US$6.36
US$60.00 (+843.40%)
Average
US$35.20 (+453.46%)
Lowest
US$17.00 (+167.30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Ulz
Morgan Stanley
Buy
Reiterated
US$28.00
+340.3%
11/02/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
US$35.00
+450.3%
10/20/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
US$28.00
+340.3%
10/19/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
US$60.00
+843.4%
10/14/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
US$36.00
+466%
10/02/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
-
-
09/14/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Initiated
US$17.00
+167.3%
08/19/2026
William Wood
B. Riley Securities
Buy
Initiated
US$34.00
+434.6%
07/23/2026
Thomas Smith
Leerink Partners
Buy
Initiated
US$36.00
+466%
03/03/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
ጁን 2025
ዲሴም 2025
ማርች 2026
ጁን 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
11.01 ሚ
13.86 ሚ
11.48 ሚ
11.48 ሚ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.34 ሚ
3.17 ሚ
6.09 ሚ
6.09 ሚ
Operating expense
13.70 ሚ
16.53 ሚ
17.03 ሚ
17.03 ሚ
Total operating expenses
13.70 ሚ
16.53 ሚ
17.03 ሚ
17.03 ሚ
Operating income
-13.70 ሚ
-16.53 ሚ
-17.03 ሚ
-17.03 ሚ
Other non operating income
-128.00 ሺ
-1.54 ሚ
-219.00 ሺ
-219.00 ሺ
EBT including unusual items
-13.43 ሚ
-17.40 ሚ
-15.49 ሚ
-15.49 ሚ
EBT excluding unusual items
-13.43 ሚ
-17.40 ሚ
-15.49 ሚ
-15.49 ሚ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-656.00 ሺ
-506.00 ሺ
-539.50 ሺ
-539.50 ሺ
Net income
-13.43 ሚ
-17.40 ሚ
-15.49 ሚ
-15.49 ሚ
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
427.50 ሺ
720.00 ሺ
1.87 ሚ
1.87 ሚ
Interest expense
-37.50 ሺ
-
-107.50 ሺ
-107.50 ሺ
Net interest expenses
390.00 ሺ
720.00 ሺ
1.76 ሚ
1.76 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.60 ሚ
-16.51 ሚ
-16.94 ሚ
-16.94 ሚ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google መተግበሪያዎች